Dr Emily Milodowski
PhD, BVSc, BSc, PG Dip VCP
Expertise
Emily is a Research Training fellow on the Wellcome Trust funded GW4-CAT programme undertaking a PhD in cancer immunology. She is investigating resistance of tumors to novel immunotherapies including PD-1 checkpoint blockade.
Current positions
Clinical Research Fellow
Bristol Veterinary School
Contact
Press and media
Many of our academics speak to the media as experts in their field of research. If you are a journalist, please contact the University’s Media and PR Team:
Biography
Emily graduated with distinction from Bristol Veterinary School in 2015, having earlier completed an intercalated BSc in Cellular and Molecular Medicine, where she graduated with first class honours. Emily subsequently worked in a small animal veterinary hospital in West Sussex before completing a Post Graduate Diploma in Veterinary Clinical Practice as an intern at the Royal Veterinary College, London. In 2017, Emily elected to further pursue her research interests in the field of immunology and was awarded a Veterinary Clinical Primer by the Elizabeth Blackwell Institute. She is currently a GW4-CAT Research Training Fellow undertaking her PhD in cancer immunology. Her project aims to investigate immune dysregulation in cancer, and elucidate mechanisms by which cancers are able to evade the immune response and impair responses to novel checkpoint blockade immunotherapies.
Publications
Recent publications
08/05/2025Hybrid B and T-cell immunity associates with protection against breakthrough infection after SARS-CoV-2 vaccination in ALSPAC participants
Journal of Infectious Diseases
Antibodies generatedin vitroandin vivoelucidate design of a thermostable ADDomer COVID-19 nasal nanoparticle vaccine
In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2
Antibody Therapeutics
Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months
eLife
Adenosine 2A receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization
Communications Biology
Thesis
Elucidating mechanisms of tumour resistance to checkpoint blockade
Supervisors
Award date
27/09/2022